Treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. Monotherapy or in combination w/ methotrexate for the treatment of active psoriatic arthritis in adults who have responded inadequately to, or who are intolerant to ≥1 DMARD therapies. Treatment of adults w/ active ankylosing spondylitis who have responded inadequately to conventional therapy. Treatment of adults w/ active non-radiographic axial spondyloarthritis w/ objective signs of inflammation as indicated by elevated C‑reactive protein &/or MRI who have responded inadequately to NSAIDs.
Discontinue immediately if serious hypersensitivity reaction occurs. Increased rate of infections eg, URTI, oral candidiasis, conjunctivitis, & tinea infections. Caution in patients w/ clinically important chronic infection or a history of recurrent infection. Must not be given to patients w/ active TB. Not recommended in patients w/ inflammatory bowel disease. Do not use w/ live vaccines. Women of childbearing potential should use effective method of contraception during treatment & for at least 10 wk after treatment. Pregnancy & lactation.
Sign Out
